

Press release

EQL PHARMA

Lund, September 23, 2025

EQL Pharma AB (publ)

556713-3425

Mellozzan® (melatonin) launched in the UK

EQL's key product Mellozzan® (tablets) has now been launched in the UK by our partner Medice. Medice specialise in ADHD and have previously launched Mellozzan® successfully in Germany, among other countries. Unlike many other countries in Europe, there is already a growing use of melatonin to treat children with ADHD and sleep problems in the UK. The melatonin tablet market had a turnover of around £10.8 million in 2024, with a volume growth of 32% compared to 2023.

Mellozzan® in the UK is expected to be expanded with the oral solution in 2026. The application is currently under review by the UK Medicines Agency.

About Mellozzan®

Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.

About Medice

Medice Arzneimittel Pütter GmbH & Co. KG, founded in 1949 and headquartered in Iserlohn (Germany), is a fully integrated pharmaceutical company with its own GxP capabilities in the development, manufacturing and pan-European and international distribution of pharmaceuticals and medical devices. It is the core of the "Medice – The Health Family" which aims to improve patient care by offering high-quality innovative pharmaceuticals, non-pharmacological interventions and value-added services. For more information, please visit www.medice.com.

For further information, please contact:

Axel Schörling

CEO & President, EQL Pharma AB (publ)

Phone: +46 (0) 76 317 90 60

E-mail: axel.schorling@eqlpharma.com

Website: www.eqlpharma.com

EQL Pharma AB (publ) briefly

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.